PROTHENA CORPORATION PUBLIC LIMITED COMPANY Cash and Restricted Cash
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) had Cash and Restricted Cash of $289.05 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $289.05M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $330.32M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $308.39M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $331.70M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $289.05M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $330.32M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $308.39M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $331.70M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $372.30M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $418.80M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $472.25M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $520.12M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $564.98M 10-Q · filed 2025-08-04 |
| 2024-03-31 | $548.72M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $621.04M 10-K · filed 2026-02-27 |
| 2023-09-30 | $673.11M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $661.32M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $688.40M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $712.62M 10-K · filed 2026-02-27 |
| 2022-09-30 | $496.98M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $510.15M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $544.35M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $580.45M 10-K · filed 2025-02-27 |
| 2021-09-30 | $601.45M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $402.54M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $345.70M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $298.08M 10-K · filed 2024-02-22 |
| 2020-09-30 | $317.23M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $336.65M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $355.39M 10-Q · filed 2021-05-11 |
| 2019-12-31 | $378.43M 10-K · filed 2023-02-28 |
| 2019-09-30 | $393.01M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $402.20M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $414.16M 10-Q · filed 2020-05-06 |
| 2018-12-31 | $431.71M 10-K · filed 2022-02-25 |
| 2018-09-30 | $455.57M 10-Q · filed 2019-11-05 |
| 2018-06-30 | $490.27M 10-Q · filed 2019-08-06 |
| 2018-03-31 | $433.10M 10-Q · filed 2019-05-07 |
| 2017-12-31 | $421.68M 10-K · filed 2021-02-26 |
| 2017-09-30 | $460.12M 10-Q · filed 2018-11-06 |
| 2017-06-30 | $475.79M 10-Q · filed 2018-08-07 |
| 2017-03-31 | $510.61M 10-Q · filed 2018-05-09 |
| 2016-12-31 | $390.98M 10-K · filed 2020-03-03 |
| 2016-09-30 | $412.63M 10-Q · filed 2017-11-07 |
| 2016-06-30 | $447.00M 10-Q · filed 2017-08-09 |
| 2015-12-31 | $370.59M 10-K · filed 2019-03-15 |
| 2014-12-31 | $293.58M 10-K · filed 2018-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |